Drug Status Report

**Drug:** 5α-Androstano-[2,3-c]-furazan-17β-tetrahydropyranol ether

**Drug Name Status:** 5α-Androstano-[2,3-c]-furazan-17β-tetrahydropyranol ether is the chemical name

**Other Names:** Furazadrol; Furazadrol-THP ether; 5α-Etioallocholan-[2,3-c]-furazan-17β-tetrahydropyranol ether

**Chemical structure:**

![Chemical structure diagram]

**Molecular Formula:** C_{24}H_{36}N_{2}O_{3}

**Pharmacological class / Application:** steroid

**International status:**

US: The substance is not listed on the schedules to the CSA and is not mentioned on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control. The drug is not listed on the Green List - List of Psychotropic Substances under International Control.

Canadian Status: 5α-Androstano-[2,3-c]-furazan-17β-tetrahydropyranol ether\(^1\) is not listed on the Schedules to the CDSA. The parent steroid, 17β-hydroxy-5α-Androstano-[2,3-c]-furazan, has been shown in *in vivo* studies to display anabolic activity\(^2\) and therefore both 17β-hydroxy-5α-Androstano-[2,3-c]-furazan and its 17β-tetrahydropyranol ether derivative are considered to be included under the heading “Anabolic steroids and their derivatives” of Item 23 of Schedule IV to the CDSA

---


Recommendation: 5α-Androstan-2,3-furazan-17β-tetrahydropyranol ether is included under Item 23 of Schedule IV to the CDSA and is a controlled substance.

16 March 2010.